[Shock in meningococcal sepsis. Aspects on its pathogenesis and treatment].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000614:Aminocaproates / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000150:complications / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008589:Meningococcal Infections / Q000150:complications* / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D012772:Shock, Septic / Q000188:drug therapy / Q000209:etiology*; D012790:Shwartzman Phenomenon / Q000150:complications / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D000614:Aminocaproates; D005938:Glucocorticoids; D009588:Nitrogen Mustard Compounds; D006493:Heparin
Shock en la sepsis meningocócica. Consideraciones sobre su patogenia y tratamiento